Back in May, a study was published
suggesting that popular weight-loss drugs such ‍as Ozempic ⁣and wegovy could
curb alcohol cravings⁢ by as much‍ as 70%. At the time, researchers‌ weren’t
‌ entirely sure why the ​GLP-1s had such⁢ a profound effect on alcohol
⁣ receptors, but that may have all changed.
‍ ​

How do GLP-1s work?

A new study⁢ published Wednesday in the journal
Scientific Reports
⁤ found ‍that GLP-1s slow the absorption of alcohol‍ into the bloodstream, thus
​ minimizing its effects on ​the brain. it’s not entirely different from what
‍ ⁢ GLP-1s do with food, which is to resemble the ​GLP-1 hormone and effectively
⁤ slow digestion.

GLP-1s,or glucagon-like peptide-1 ⁤receptor agonists,are a class of
medications originally developed to treat Type 2 Diabetes. Thay work by
mimicking ⁤the effects of the naturally occurring GLP-1 hormone, which
regulates blood sugar levels. This⁣ mimicking action extends to slowing
‌ ‌ gastric emptying, meaning ⁢food and liquids, including⁣ alcohol, remain in the
stomach longer.

the study‌ involved administering alcohol to ⁤rats both with and without⁢ GLP-1
treatment. Researchers observed that the rats treated with GLP-1s exhibited
⁤ considerably‍ lower ​blood alcohol concentrations compared to the​ control
⁢ ​ group. This suggests that the medications physically delay‌ the rate at which
‍ alcohol enters the bloodstream.
‍

‌ Implications⁢ for Alcohol Use⁢ Disorder

‌ The​ findings ⁣have significant implications for individuals struggling with
⁣ alcohol use disorder (AUD). By reducing the reinforcing effects of alcohol –
the “buzz” – GLP-1s could potentially diminish cravings and support
⁢ ‌ abstinence.
⁣

​ However, experts caution against viewing GLP-1s as a “cure” for AUD.Dr.Lori Pbert, a professor of⁣ medicine‍ at the University of Massachusetts
Medical School, notes that “These medications are not a magic bullet.
They need to be part of a⁤ comprehensive treatment plan that includes
​ therapy,support groups,and lifestyle changes.”
​ ‍

‍ ‌ Further research is needed ⁢to determine the optimal dosage, duration of
⁤ treatment, and​ potential side effects of using GLP-1s for AUD.‌ Clinical
⁢ trials are ⁤currently‌ underway to investigate these questions.
⁢

Potential Benefits & Risks